HHS Accountability Project publication
Unforgivable Hypocrisy From FDA’s Career CDER Leadership
David Gortler
The same career FDA bureaucrat who loudly crowed about “following the science” to discredit President Trump has approved a failed Alzheimer’s drug.
Articles
Forbes / July 19, 2021
Separate Payments for Abortion Services and Other Changes in HHS’s Proposed Insurance Regulations
Rachel N. Morrison
A new rule proposed by HHS would, among other changes, reverse Trump-era insurance regulations requiring separate billing and collection of payments for certain abortion services.
Articles
Federalist Society Commentary / July 13, 2021
Revisiting Harris Funeral Homes’ Compelling Government Interest Analysis After Fulton
Rachel N. Morrison
After Fulton, the Sixth Circuit’s compelling interest analysis in Harris Funeral Homes cannot stand. Courts cannot credit the alleged compelling government interest of non-discrimination by ignoring the constitutional guarantee of free exercise.
Articles
National Review Online / July 8, 2021
Why Unanimity Was So Important in the Fulton Case
Roger Severino
With its 9-0 ruling in favor of the Fulton plaintiffs, the Supreme Court is saying people with sincere faith-informed understandings of social issues that cut against the grain of secularist thought aren’t to be treated as bigots, and government needs to back off.
Articles
National Review Online / June 18, 2021
Breaking: EEOC Chairwoman Unilaterally Issues Gender Guidelines
Roger Severino
Charlotte Burrows, chairwoman of the Equal Employment Opportunity Commission (EEOC), posted a guidance document purporting to apply Bostock v. Clayton County, which redefined Title VII’s prohibitions on discrimination “because of sex” to include sexual orientation and transgender status in certain contexts.
Articles
National Review Online / June 15, 2021
FDA’s New CDER Director Grants Approval of Yet Another Expensive, Scientifically Questionable Drug … More…
David Gortler
Since the FDA operates without external oversight, it’s not possible to hold the agency accountable for bad approval decisions that ultimately place taxpayers on the hook for hundreds of billions of dollars via Medicare Part B program.
Articles
Forbes / June 11, 2021
Why Would Planned Parenthood Care About Donor Disclosure Laws When HHS Is Handing Them Millions…
Rachel N. Morrison
Planned Parenthood is directly implicated in litigation currently before the Supreme Court on a donor disclosure law, but is mysteriously silent on the issue.
Articles
The Federalist / June 3, 2021
EPPC Scholar Comment at HHS COVID-19 Health Equity Task Force Meeting
Rachel N. Morrison
EPPC Policy Analyst Rachel N. Morrison offered comment at HHS’s COVID-19 Health Equity Task Force meeting, urging the task force “to ensure that your efforts to promote equity do not encourage or enable illegal discrimination.”
Articles, Testimony
Publications / May 28, 2021
Drug Quality “Trumps” Drug Pricing
David Gortler
There is an enormous national security risk to relying on geopolitical adversaries like China for America’s life-saving drugs. This is similar to the risk that both the Republican and Democrat parties recognized with respect to our energy supplies, where a renewed focus on domestic production enabled the U.S. to become a net oil exporter by 2019. The move to energy independence created good paying jobs for thousands of Americans.
Articles
Forbes / May 25, 2021
Biden’s HHS Chooses Ideology Over Science on Transgender Issues
Roger Severino
HHS Secretary Xavier Becerra and Assistant Secretary of Health Dr. Rachel Levine seem to want to intimidate scientists, health care providers and insurers into bowing to gender identity politics without having to explain their actions to the public.
Articles
Newsweek / May 20, 2021
EPPC Scholar Comment Opposing Proposed Title X Rule on Abortion Funding
Rachel N. Morrison
EPPC Policy Analyst Rachel N. Morrison submitted a public comment to the U.S. Department of Health and Human Services (HHS) objecting to HHS’s proposed Title X rule that would funnel millions of taxpayer dollars to abortion providers by undoing a Trump-era regulation that ensured separation between Title X funded programs and abortion activities.
Articles
Publications / May 17, 2021
China Is at War with the FDA. Guess Who’s Winning.
David Gortler
China is allowing only those tested for COVID-19 and vaccinated with its proprietary vaccines to enter their country. This represents a problem when it comes to the regulation of drugs for American consumers: China’s vaccine entry requirements make it nearly impossible for the FDA to fully staff regulatory operational activity in China.
Articles
Forbes / April 23, 2021